Ahead Therapeutics, a biotech company developing a platform technology to induce antigen-specific immune tolerance for the treatment of autoimmune diseases, has received positive feedback from the European Medicines Agency (EMA), smoothing the path to begin regulatory toxicology studies for its lead program, Myasthenia Gravis. This regulatory milestone highlights the strength of the company’s preclinical data and represents a critical step toward clinical development.
The feedback from the EMA reinforces Ahead Therapeutics’ scientific approach, which leverages autoantigen-encapsulating PS-liposomes to selectively and durably reprogram immune responses. The company’s platform holds promise for treating autoimmune diseases without the need for chronic immunosuppression. In addition to its leading asset in Myasthenia Gravis, Ahead Therapeutics’ pipeline includes programs in Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, Celiac Disease, Neuromyelitis Optica, and Immune Thrombotic Thrombocytopenic Purpura.
In parallel with its regulatory progress, Ahead Therapeutics is actively articulating its Series A financing round to support the transition into clinical development and accelerate the growth of its therapeutic pipeline. The funding will be used to initiate regulatory toxicology and first-in-human clinical studies and advance additional preclinical programs. Ahead Therapeutics welcomes conversations with investors, strategic partners, and collaborators who share its vision of transforming the treatment landscape for autoimmune diseases.
“We are thrilled to have received this positive answer from the EMA,” said Marti Dalmases, CEO of Ahead Therapeutics. “This recognition underscores the strength of our preclinical data and brings us closer to offering a novel therapeutic option for patients with autoimmune diseases.”
About Ahead Therapeutics Platform for Immune Tolerance
Ahead Therapeutics’ proprietary technology is designed to induce long-lasting immune tolerance by biomimicking a natural physiological process that the body uses to recognize self-tissue and maintain immune balance. This approach selectively targets disease-driving immune responses while preserving healthy immune function, offering a promising new strategy for treating autoimmune diseases with fewer side effects.
About Ahead Therapeutics
Ahead Therapeutics is a Barcelona-based preclinical-stage biotechnology company focused on developing antigen-specific immune tolerance therapies. Its proprietary platform aims to selectively reprogram immune responses, offering a targeted and durable alternative to traditional immunosuppression.
Founded in 2017, Ahead Therapeutics is a spin-off of the Research Institute Germans Trias I Pujol (IGTP) and the Catalan Institute of Nanoscience and Nanotechnology (ICN2).